Previous 10 | Next 10 |
Expanding our reach in 2024, HippoFi and PUR Biologics are setting new standards in innovative spine care solutions . IRVINE, CA / ACCESSWIRE / December 5, 2023 / (OTC PINK:ORHB) HippoFi's wholly owned subsidiary, PUR Biologics, is advancing its distribution network with a significant expan...
Scientist, inventor, business expert, and holder of more than 140 patents will bring forward PUR Biologics' regenerative therapeutic patent portfolio to address unmet needs in the $200 billion osteoarthritis, pain, and cartilage & spinal disc regeneration markets. IRVINE CA / ACCESSWIRE /...
PUR Biologics' robust distribution channels prove to expand sales globally. IRVINE, CA / ACCESSWIRE / October 24, 2023 / Following a successful engagement at the North American Spine Society (NASS) conference, healthcare technology company, HippoFi, Inc. (OTC PINK:ORHB), announces its wholly...
IRVINE, CA / ACCESSWIRE / September 12, 2023 / Solidifying its role as a leader in medical advancements, PUR Biologics, a wholly-owned subsidiary of HippoFi (OTC PINK:ORHB), proudly announces its latest patent acquisition, further strengthening its reputation in the biotech sector. This patent i...
HippoFi (OTC: ORHB) , a leading health care technology company and authority in spinal biologics, has announced a partnership with global medical technology leader Zimmer Biomet, aiming to redefine the spinal biologics landscape. According to the announcement, the collaboration will harness the c...
IRVINE, CA / ACCESSWIRE / September 6, 2023 / HippoFi, Inc. (OTC PINK:ORHB) proudly announces a partnership with global medical technology leader ZIMMER BIOMET, aiming to redefine the spinal biologics landscape. This collaboration will harness the combined expertise of both companies to introduc...
IRVINE, CA / ACCESSWIRE / September 1, 2023 / HippoFi, Inc. (OTC PINK:ORHB) - HippoFi, in association with its wholly owned subsidiary PUR Biologics, is preparing to unveil the details of the closing of its strategic partnership and asset acquisition with a top 5 global leader in the orthopedic ...
HippoFi (OTC: ORHB) , formerly ORHub Inc., and its wholly owned subsidiary, PUR Biologics, has received a new patent; according to the announcement, the patent covers advanced cartilage regeneration and arthritis solutions that mark a significant advancement in treating the destructive effects of...
IRVINE, CA / ACCESSWIRE / August 14, 2023 / PUR Biologics, a wholly owned subsidiary of HippoFi (OTCPK:ORHB), proudly announces its newly granted patent, marking a significant advancement in addressing the debilitating effects of osteoarthritis and cartilage degeneration. This addition to the Co...
HippoFi (OTC: ORHB) , a leading health care technology company and authority in spinal biologics, today announced its execution of an exclusive deal with Italian biomedical manufacturing company, BPB Medica. This comes as HippoFi’s PUR Biologics is preparing to launch PURmarrow360 througho...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the ...
(NewsDirect) In the domain of stock trading, opportunities often arise in unexpected places, including stocks priced under $0.10. Despite being often overlooked, these stocks can pack a punch in terms of potential gains, catching the eye of savvy investors. Let’s take a look at a f...
(NewsDirect) Orthobiologics represents a dynamic field within healthcare where the body's natural healing mechanisms address osteoarthritis and enhance recovery from tendon and ligament injuries. These therapies signify a significant evolution in medical treatment, offering promising solution...